Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Prostate Cancer (U.S. Physician and Payer Perspectives on Novel Treatment Options for Prostate Cancer) | Physician & Payer Forum | US | 2015
The U.S. Physician and Payer Perspectives on Novel Treatment Options for Prostate Cancer report surveyed 50 medical oncologists, 52 urologists, and 30 MCO pharmacy and medical directors to capture…
The Burgeoning Prostate Cancer Market in the EU5 | Physician & Payer Forum | EU5 | 2015
Five premium-priced therapies – Xtandi (Medivation/Astellas Pharma), Provenge (Dendreon), and Xofigo (Algeta/Bayer HealthCare), Zytiga (Janssen), and Jevtana (Sanofi) – are approved in Europe…
Global Forecast of the Coming Ten Years in the Epidemiology and Treatment Opportunities for Prostate Cancer
Over the next ten years, more than 15 million men worldwide will be diagnosed with prostate cancer, resulting in nearly 3 million first-line drug-treatment opportunities in the metastatic castrate-…
Prostate Cancer (First-Line [Chemotherapy-Naive] Metastatic Castrate-Resistant) | DecisionBase | US | 2015
What Advantages Do Surveyed Oncologists and Payers Believe Emerging Therapies Must Offer to Gain Traction in This Increasingly Competitive Market? In recent years, several new, high-priced…
Impact of Improving Cancer Survival on Drug-Treatment Opportunities: The Case of CML and Prostate Cancer
Earlier diagnosis and advances in treatment have reduced cancer patients’ mortality over the past decade in the mature markets. Developing markets will continue to see benefits in cancer survival…
The Metastatic Castrate-Resistant Prostate Cancer Patient Journey: EU5 Prescribing Preferences and Payer Strategy as Options Diversify | Physician & Payer Forum | EU5 | 2014
Three new premium-priced therapies–Xtandi (Medivation/Astellas Pharma), Provenge (Dendreon), and Xofigo (Algeta/Bayer HealthCare)–have recently been approved in Europe for prostate cancer…
Prostate Cancer (First-Line [Chemotherapy-Naive] Metastatic Castrate-Resistant) | Decision Base | US/EU | 2014
As Abiraterone and Enzalutamide Gain Traction in the Market, What Key Attributes Do Oncologists and Payers Say Will Differentiate Emerging Therapies? The first-line (chemotherapy-naive)…
